Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713741 | PMC |
| http://dx.doi.org/10.1093/noajnl/vdab178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benign Enchondroma in a 40-Year-Old Female: Emphasizing the Importance of Early 18F-FES PET/CT Utilization.
Case Rep Radiol
August 2025
Independent Researcher, Ellicott City, Maryland, USA.
A 40-year-old female with estrogen receptor-positive breast cancer underwent an initial staging using a technetium-99m methylene diphosphonate (Tc-99m MDP) bone scan, which revealed abnormal uptake in the femur without a patient history of prior trauma or associated symptoms. Subsequently, an MRI confirmed the presence of a well-defined lesion in the upper left femur. To rule out metastatic disease, an 18F-fluoroestradiol (FES) PET/CT was performed, demonstrating no ER expression.
View Article and Find Full Text PDFA case of invasive lobular carcinoma, highlighting the emerging role of F-Fluoroestradiol PET.
Radiol Case Rep
October 2025
Department of Radiology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
Invasive lobular carcinoma (ILC) presents significant diagnostic challenges due to its subtle presentation on mammography. Its low metabolic activity further limits the detection of metastatic lesions using fluorine-18 (F)-fluorodeoxyglucose-positron emission tomography (FDG-PET). In contrast, F-fluoroestradiol-PET (FES-PET), which targets functional estrogen receptor (ER) expression, enhances visualization of ER-positive metastases.
View Article and Find Full Text PDFThe Role of [F]FES PET/CT in Breast Cancer Management: An Umbrella Review.
Cancers (Basel)
May 2025
Department of Gynaecology and Obstetrics, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Lugano, Via Tesserete 46, 6900 Lugano, Switzerland.
Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Estrogen receptor (ER) status is a key determinant in the diagnosis and treatment of BC. Although immunohistochemistry (IHC) is the gold standard for ER assessment, it has limitations.
View Article and Find Full Text PDFF-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
J Nucl Med
May 2025
Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California; and
F-fluoroestradiol (F-FES) PET/CT has been investigated as a potential biomarker to predict response to endocrine therapies in patients with estrogen receptor (ER)-positive breast cancer. Although previous findings were promising, most had limited statistical significance because of small individual sample sizes. Therefore, we performed a systematic review and metaanalysis of the F-FES PET/CT literature to increase our power to evaluate the utility of F-FES PET/CT as a biomarker for prediction of clinical benefit from endocrine therapy in patients with ER-positive breast cancer.
View Article and Find Full Text PDFFluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Breast Cancer Res
February 2025
University of Washington, Seattle, WA, USA.
Background: F-Fluorodeoxyglucose (FDG) and F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) positive metastatic breast cancer (MBC), but little is known about its utility in patients with breast tumors that overexpress human epidermal growth factor 2 (HER2). We hypothesize that comparing patterns of FDG and FES uptake in patients with HER2-positive versus HER2-negative MBC can guide further biologic and clinical studies into the HR/HER2-positive phenotype.
Methods: We conducted a retrospective study examining uptake in matched lesions for FES and FDG-PET scans, assessing these parameters in 213 patients with ER-positive/HER2-positive (n = 33) versus ER-positive/HER2-negative MBC (n = 180).